Fundraisings and IPOs

Date: 2015-06-10

Type of information: Series D financing round

Company: Melinta Therapeutics (USA - CT)

Investors: Malin Corporation (Ireland) other existing investors, including Vatera Healthcare Partners.(USA - NY)

Amount: $67 million

Funding type: series D financing round

Planned used:   Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program.  

Others:

• • On June 10, 2015, Melinta Therapeutics announced the successful completion of a $67 million Series 4 equity financing. Malin Corporation plc led the round and was joined by other existing investors, including Vatera Healthcare Partners.

Therapeutic area: Infectious diseases

Is general: Yes